ARTICLE SUMMARY:
The success of transcatheter aortic valve replacement (TAVR) devices set the stage for transcatheter technology to move to the mitral space, a potentially much larger opportunity. The question remained: when would the deal-making begin, indicating that the large strategic players acknowledge this potential opportunity and validating the efforts of entrepreneurs and investors who had launched numerous transcatheter mitral valve (TMV) start-ups? The answer is now.
TAVR’s success set the stage for transcatheter technology to move to the mitral space, a potentially much larger opportunity.
